GenoMed Submits Formal Application to Chinese Government to Work With SARS Patients
ST. LOUIS, MO, May. 15, 2003 (MARKET WIRE via COMTEX) -- GenoMed, Inc -- ("the Company" or "GenoMed") (OTC: GMED), a St. Louis, Missouri-based medical genomics and Next Generation Disease Management(TM) company, announced today that it has been invited to apply to the Chinese Government for permission to conduct a clinical trial for its potential treatment for SARS (severe acute respiratory syndrome).
Dr. Larry Wu, Second Secretary for Science and Technology in the Chinese Embassy in Washington, D.C., first contacted GenoMed on April 30, 2003 about its potential treatment for SARS. Dr. Wu has just invited GenoMed to participate in the peer-review process for possible selection to conduct clinical trials in China.
Dr. David Moskowitz, Chairman, CEO, and Chief Medical Officer of GenoMed, said, "We are extremely grateful to Dr. Wu for believing that our approach to SARS, using already existing medications, may have merit, just as we are to Dr. Cathy Laughlin, Chief of Virology at the National Institute for Allergy and Infectious Disease (NIAID) at the National Institutes of Health. I spoke with Dr. Laughlin yesterday, and she encouraged me to pursue my already established contact with Dr. Wu, since there are no SARS patients yet in the US. Dr. Wu has graciously agreed to submit our proposal to a special committee of scientists and physicians in China established to combat the SARS epidemic in that country."
Dr. Moskowitz continued, "I've never been to China before, so I'm thrilled at the prospect of seeing this great culture with my own eyes. Conducting the clinical trial by remote control was not an option. But I'm not worried about the visit. If I'm right, the high-dose ACE inhibitor I'm taking now to prevent cardiovascular disease and colon cancer, which run in my family, will also protect me against SARS. If I'm wrong, I'll find out soon enough."
Dr. Moskowitz ended by saying, "The time frame on this is open-ended. It may take months for the review process to even get to GenoMed's proposal. Given the large number of competing claims being made about anti-viral therapy in particular, GenoMed's approach may never be selected for a clinical trial in China. But my take on SARS is that the epidemic will not disappear, and that there will be other countries in a position to consider trying GenoMed's inexpensive approach. Sooner or later, we'll get a chance to prove whether it works. Once we do, we'll charge royalties. Meanwhile, our work continues on non-headline epidemics, like kidney failure, cancer, HIV, and autoimmune diseases. We currently have around 200 patients from around the world enrolled in inexpensive clinical trials for these diseases. These trials are being conducted by 'remote control.'"
Click here to learn more about our clinical trials:
216.234.225.2/sendFeedBack.asp?B=571&RL=3260&S=5036 GenoMed
GenoMed, Inc. is a Next Generation Disease Management(TM) whose mission is to improve patient outcomes by identifying and exploiting the molecular pathways that cause disease. A St. Louis Business Journal article (www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) first reported that the company had applied for patents based on its finding that the ACE gene is associated with a large number of common diseases including HIV infection, AIDS, and autoimmune diseases. The Company has filed world-wide patent applications on its new treatments, and is eager to license them globally. GenoMed's research results are more fully described on its website, www.genomedics.com.
For questions, please contact David W. Moskowitz MD, MA(Oxon.), FACP at 314-977-0110, FAX 314-977-0042, email: dwmoskowitz@genomedics.com or visit us at www.genomedics.com.
CONTACT: David W. Moskowitz MD, MA(Oxon.), FACP
GenoMed
314-977-0110 |
